Systematic review and meta-analysis: efficacy and safety of early biologic treatment in adult and paediatric patients with Crohn's disease
- 1 May 2020
- journal article
- review article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 51 (9), 831-842
- https://doi.org/10.1111/apt.15685
Abstract
Background There is an increasing body of evidence showing that earlier use of biologics improves clinical outcomes in Crohn's disease (CD). Aim To perform a systematic review and meta-analysis to assess the impact of early biologic use in the treatment of CD. Methods PubMed and Embase databases were searched for English language papers and conference abstracts published through April 30, 2019. Studies were selected for inclusion if patients initiated biologics within 2 years of a CD diagnosis or if earlier biologics use (top-down) was compared with a conventional step-up strategy. Random-effects meta-analyses were conducted to compare clinical remission (CR), relapse and endoscopic healing rates between early biologic treatment (2 years of disease duration or conventional step-up treatment strategy). Results A total of 3069 records were identified, of which 47 references met the selection criteria for systematic review. A total of 18 471 patients were studied, with a median follow-up of 64 weeks (range 10-416). Meta-analysis found that early use of biologics was associated with higher rates of clinical remission (OR 2.10 [95% CI: 1.69-2.60], n = 2763, P < .00001), lower relapse rates (OR 0.31 [95% CI: 0.14-0.68], n = 596, P = .003) and higher mucosal healing rates (OR 2.37 [95% CI: 1.78-3.16], n = 994, P < .00001) compared with late/conventional management. Conclusions Early biologic treatment is associated with improved clinical outcomes in both adult and paediatric CD patients, not only in prospective clinical trials but also in real-world settings.Funding Information
- AbbVie
This publication has 65 references indexed in Scilit:
- Efficacy of Early Infliximab Treatment for Pediatric Crohn's Disease: A Three-year Follow-upPediatric Gastroenterology, Hepatology & Nutrition, 2012
- Infliximab Therapy Impacts the Peripheral Immune System of Immunomodulator and Corticosteroid Naive Patients with Crohn' DiseaseGut and Liver, 2011
- Infliximab therapy in children with Crohn’s disease: a one‐year evaluation of efficacy comparing ‘top‐down’ and ‘step‐up’ strategiesActa Paediatrica, 2011
- Risk Factors Associated With Progression to Intestinal Complications of Crohn's Disease in a Population-Based CohortGastroenterology, 2010
- S1031 Crohn's Disease Mucosal Healing in Adalimumab-Treated Patients is Affected by Disease Duration: Results From ExtendGastroenterology, 2010
- Mucosal Healing Predicts Sustained Clinical Remission in Patients With Early-Stage Crohn's DiseaseGastroenterology, 2010
- Top-down therapy for IBD: rationale and requisite evidenceNature Reviews Gastroenterology & Hepatology, 2010
- Efficacy of early treatment with infliximab in pediatric Crohn’s diseaseWorld Journal of Gastroenterology, 2010
- S1136 Increased Risk of Clinical Relapse Is Associated with Longer Disease Duration in Crohn's DiseaseGastroenterology, 2009
- Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the diseaseGut, 2001